Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biomarck Announces Positive Results from NSCLC Study | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Biomarck Announces Positive Results from NSCLC Study

Statistical significance was achieved in improvement of Overall Response Rate in the in the BIO-11006/SOC group

By: Cassandra Gervolino

Biomarck Pharmaceuticals, Ltd announced that statistical significance (p=0.02) was achieved in improvement of Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase II study in NSCLC. 
 
BIO-11006/SOC also showed less Disease Progression (DP) than SOC alone (7% to 17% respectively) and more Partial Response (PR) than SOC (40% to 30%).
 
BIO-11006 was well tolerated with cough, dyspnea and headache being most commonly (5%) related adverse events. BIO-11006 has, in Invitro studies, shown activity against all solid tumors tested including lung, breast, colon and sarcoma. It is part of a portfolio of over 100 patented compounds owned by Biomarck.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters